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Background: Dilated Cardiomyopathy (DCM) is one of the most commonly encountered heart diseases reported
globally. It is characterized by enlarged ventricles with impaired systolic and diastolic functions. Mutations in
LMNA gene are one of the causative factors to precipitate the disease. However, association of SNPs of LMNA
with DCM in particular has not been well documented.
Method: Here we present a limited and restricted case study of patients from south eastern part of India afﬂicted
with idiopathic DCMand conduction defects. By using next generation sequencingwe have sequenced the exons
of LMNA gene from genomic DNA isolated from patients.
Result:Wehave identiﬁed the linkage of 8 different LMNA SNPswith idiopathic DCMviz. rs121117552, rs538089,
rs505058, rs4641, rs646840, rs534807, rs80356803 and rs7339. These SNPs are scattered throughout the gene
with prevalence for the region encoding the central rod domain of lamin A/C.
Conclusion:Most of these SNPs in LMNAwere previously reported to be involved in various disorders other than
DCM.We conclude that, variation in LMNA is one of the major underlying genetic causes for the pathogenesis of
DCM, as observed in few Indian populations.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Dilated Cardiomyopathy (DCM) is a disease of the heart muscle
which is characterized by ventricular dilation and reduced myocardial
contractility thereby resulting into impaired systolic and diastolic
function [1]. Clinical symptoms include heart failure, thromboembolism
and sudden cardiac death. DCM is the most common among the ﬁve
commonly characterized cardiomyopathies. It has an estimated preva-
lence of 1/2500 among different populations [2,3]. The pattern of the
disease inheritance ismostly autosomal dominant [4]. However, genetic
screening shows only 30–35% familial DCM follow theMendelianmode
of disease inheritance [5] while the remaining idiopathic origin DCM
follows a complex multivariant origin. Extensive epidemiological stud-
ies are still limited to US, European, and Australian populations and
also to some Asian countries like Japan, China and Korea where a total
of 165 LMNA mutations have been reported (http://www.umd.be/
LMNA/) [6–13].omics Division, Saha Institute of
.
upta).
land Ltd. This is an open access articleMore than 40 genes have been reported so far to be associated with
the pathogenesis of DCMwhich is a heterogeneous disease [14]. 6% of all
DCM cases are caused by mutations in lamin A/C gene (LMNA). Fatkin
et al. in 1999 [15] ﬁrst showed the involvement of LMNA mutations
with DCM and conduction diseases. All these studies suggest that the
LMNA related DCM patients portend a high risk of sudden cardiac death.
LMNA consists of 12 exons and encodes two splice variants lamin A
and C which maps in the long arm of chromosome 1 (1q21.2–q21.3)
[16]. Mutations in LMNA are known to cause a wide spectrum of dis-
eases other than DCM, in a tissue speciﬁc manner collectively termed
as laminopathies namely Lipodystrophy, Limb–girdle muscular dystro-
phy, Emery–Dreifuss muscular dystrophy and many more [17,18].
Most LMNA mutations causing striated muscle disorder are missense
mutations distributed throughout all the exons of the gene. Along
with mutations in LMNA, various Single Nucleotide Polymorphisms
(SNPs) in LMNAwere reported to be associated with different disorders
other than laminopathies. A total of 40 LMNA SNPs are reported in
Leiden Open Variation Database (www.dmd.nl/lmna_seqvar.html).
Out of 40, 30 are silent mutations and the rest are missense mutations
[19]. A frequently occurring LMNA SNP, rs4641 at exon 10 was found
to be associated with various disorders such as adipose tissue metabo-
lism and obesity related phenotypes [20–22]. In spite of having such a
high prevalence rate, still LMNA related DCM patients suffer from poorunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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arrhythmias. The underlying cause of DCM due to LMNA mutations is
still largely unknown and it lacks proper genotype–phenotype correla-
tion. Therefore, the severity of LMNAmutations or variations in DCMpa-
tients calls for the genetic testing of LMNA in patients for early
prognosis and to clinically manage complications of the disease on a
wider population.
Increasing number of patients in West Bengal, India is diagnosed
with DCM each year which is a serious health concern. Patients come
to the clinic complaining of respiratory distress, cough and chest pain,
edema of distal extremities, palpitations and syncopal or presyncopal
attack. A combination of investigations according to the recommenda-
tions of American Heart Association (AHA) [2] and World Health Orga-
nization (WHO) [24] form the major diagnostic approaches for DCM
patients. We have speciﬁcally focused into such a tertiary care center
at Kolkata-N.R.S. Medical College and Hospital which receives a number
of patients from Kolkata and its surrounding districts afﬂicted with
DCM. We have conﬁned our studies on IDCM. We report for the very
ﬁrst time the association of LMNA SNPs with IDCM patients of eastern
zone of India. Through genetic analysiswe have revealed the association
of 8 different LMNA SNPswith IDCMpatients. Among these 8 SNPs, SNPs
rs538089, rs505058, and rs4641 were previously reported to be associ-
ated with DCM in French population [25]. The rests of the SNPs
rs121117552, rs646840, rs534807, rs80356803, and rs7339 were
hitherto reported for other diseases but not DCM.
2. Materials and methods
2.1. Clinical assessment and screening of subjects for DCM
The clinical investigation and management of DCM started with the
acquisition of patient's history on admission. Following the history of
the patients the physicians would diagnose for DCM and screen them,
following the recommendations of AHA [2] and WHO guidelines [24].
The investigations included Chest X-ray, ECG and echocardiography
and coronary angiography (if needed). Echocardiography is still
regarded as the gold standard for diagnosis. Written informed consent
was obtained in accordance with the study protocol approved by the
local ethical committee. The study protocol conforms to the ethical
guidelines of the 1975 Declaration of Helsinki. A cohort of 10 unrelated
patients with diagnosed IDCM and suitable 12 control individuals were
selected for our study fromN.R.S. Medical College and Hospital, Kolkata,
India.
2.2. Isolation of genomic DNA from peripheral blood samples
4–5 ml of blood was drawn from the antecubital vein and
transported in ice from the hospital to the laboratory in a 6 ml sterile
EDTA containing vial. The blood was then transferred into the 15 ml
polypropylene conical centrifuge tube and the volume was adjusted to
15 ml by adding RBC lysis buffer (150 mM NH4Cl, 1 mM NaHCO3)
followed by incubation at room temperature for 15 min. The cells
were pelleted at 3000 rpm in a clinical centrifuge. This step was repeat-
ed 3–4 times until WBC was found. The supernatant was carefully
decanted and 3 ml of nucleic acid lysis buffer (10 mM TRIS pH 8,
400 mM NaCl, 2 mM Na2EDTA, SDS 0.5%) was added followed by the
addition of 100 μl proteinase K (10 mg/ml) and vortexed. The sample
was then incubated at 56 °C for 1–2 h. Then equal volume of water sat-
urated phenol was added and mixed. The mixture was centrifuged at
12,000 rpm for 12 min and this step was repeated 2–3 times followed
by the addition of equal volume of chloroform. It was centrifuged at
12,000 rpm for 12 min and the supernatant was transferred to a fresh
tube to which 1/10 volume of 10 M ammonium acetate and 2.5 times
ice cold 100% ethanol was added and mixed gently until the precipitate
formed. Itwas then centrifuged at 12,000 rpm for 12min and the super-
natant discarded. The pellet that was formedwaswashedwith 1ml ice-cold 70% ethanol. After centrifugation the ethanol was carefully
aspirated as not to dislodge the pellet which was air dried and subse-
quently dissolved in 300–500 μl of TE buffer. This constituted the geno-
mic DNA.
2.3. Genetic testing
Genomic DNA isolated from peripheral lymphocytes of subjects was
used as a template for genetic testing of the LMNA gene. The LMNA gene
was ampliﬁed using 29 sets of primerswhich cover the entire coding re-
gion of the LMNA (Table 1); 12 coding exons as well as the immediate
intronic regions. Sequencing was performed in Ion Personal Genome
Machine® (PGM™) System using Ion PGM™ Sequencing 200 Kit v2
(following the manufacture's protocol). The SNPs obtained from next
generation sequencing were further validated by Sanger sequencing.
The 12 sets of primers reported in Perrot et al. [9], were used for
sequencing the desired exons of LMNA by Sanger sequencing.
3. Results
3.1. Clinical status
A cohort of 10 subjects coded by S1 through S10, diagnosed with
IDCM, from a tertiary care center at Kolkata-N.R.S. Medical College and
Hospital were selected randomly irrespective of age and sex. The age
group in the cohort varied from 12 to 80 years. The presence of the dis-
ease was classiﬁed as sporadic in all the patients. Subjects diagnosed
with DCMusually showed symptoms of respiratory distress on exertion
and also on rest, cough, fatigability and edema. Irregular pulses, narrow
pulse pressure, atrial ﬁbrillation, and elevation of jugular venous pres-
sure were routinely observed. Cardiac examinations of the decompen-
sated DCM patients revealed mufﬂed heart sound with gallop rhythm
(LVS3 or RVS3). The apexwas down and out and therewas the presence
of systolic murmur at apexwhichwas indicative ofmitral regurgitation.
Chest X-ray in patients revealed cardiomegaly with or without pulmo-
nary congestion. ECG showed the following abnormalities – LBBB (left
bundle branch block), LVH, ST-T and atrial ectopic, ventricular ectopic
and also atrial ﬁbrillation as shown in Fig. 1. Echocardiography which
is regarded as the gold standard showed dilatation of cardiac chambers,
generalized hypokinesia, low ejection fraction and occasionalmitral and
tricuspid regurgitation as shown in Fig. 2. Detailed clinical statuses of
DCM patients are summarized in Table 2.
3.2. Genetic analysis of LMNA
Genetic analysis of the subjects was performed by screening 12 cod-
ing exons as well as the immediate intronic regions of LMNA gene,
which were ampliﬁed by PCR using 29 sets of primers as detailed in
Table 1. Using next generation sequencing technique, we identiﬁed
the association of 8 different LMNA SNPs with 5 out of 10 DCM subjects
in our study. All the subjects were found to be heterozygous for the
identiﬁed SNPs. The identiﬁed LMNA SNPs (as shown in Table 3) were
(a) rs121117552 c.612GNA L204L located at exon 3, (b) rs538089
c.816TNC A287A located at exon 5, (c) rs505058 c.1338TNC D446D lo-
cated at exon 7, (d) rs4641 c.1698 CNT H566H located at exon 10
(e) rs646840 c.937-83GNT located in the intron region, (f) rs534807
c.1157+16GNA also residing in the intron region, (g) rs80356803
c.128TNC located in 5′UTR and (h) rs7339 c.76GNC located in the 3′
UTR (Fig. 3). Out of the 10 patients surveyed, we observed 4 cases viz.
S1, S3, S7 and S9withmultiple LMNA SNPs. Patient S1 scoredmaximum
for 3 SNPs rs505058, rs646840 and rs534807 and remaining 3 patients
with 2 SNPs each. However, SNP rs534807was also identiﬁed in another
patient named S3. Patient S3 also harbored rs4641 (Table 3). rs4641was
the most frequently encountered SNP in this cohort, which was
identiﬁed in three different individuals S3, S4 and S9 (Table 3). SNP
rs121117552 was identiﬁed in one single patient named S8; rs538089
Table 1
Primers for Ion PGM™ sequencing.
Primer ID Start position End position Amplicon Id Start position End position
(Without the common tail)
LMNA_PP1_1F 156084537 156084556 LMNA_PP1_1 156084557 156084748
LMNA_PP1_230R 156084749 156084767
LMNA_PP1_162F 156084698 156084716 LMNA_PP1_162 156084717 156084906
LMNA_PP1_390R 156084907 156084926
LMNA_PP1_346F 156084882 156084900 LMNA_PP1_346 156084901 156085090
LMNA_PP1_574R 156085091 156085110
LMNA_PP2_1F 156100366 156100394 LMNA_PP2_1 156100395 156100550
LMNA_PP2_202R 156100551 156100567
LMNA_PP2_52F 156100417 156100439 LMNA_PP2_52 156100440 156100600
LMNA_PP2_267R 156100601 156100633
LMNA_PP3_1F 156104135 156104160 LMNA_PP3_1 156104161 156104365
LMNA_PP3_54F 156104187 156104208 LMNA_PP3_54 156104209 156104365
LMNA_PP3_250R 156104366 156104385
LMNA_PP4_1F 156104537 156104559 LMNA_PP4_1 156104560 156104723
LMNA_PP4_210R 156104724 156104751
LMNA_PP4_122F 156104659 156104679 LMNA_PP4_122 156104680 156104852
LMNA_PP4_334R 156104853 156104872
LMNA_PP5_1F 156104895 156104916 LMNA_PP5_1 156104917 156105093
LMNA_PP5_220R 156105094 156105115
LMNA_PP5_183F 156105074 156105094 LMNA_PP5_183 156105095 156105304
LMNA_PP5_230F 156105123 156105146 LMNA_PP5_230 156105147 156105304
LMNA_PP5_432R 156105305 156105326
LMNA_PP6_1F 156105515 156105540 LMNA_PP6_1 156105541 156105739
LMNA_PP6_242R 156105740 156105757
LMNA_PP6_204F 156105715 156105738 LMNA_PP6_204 156105739 156105958
LMNA_PP6_466R 156105959 156105981
LMNA_PP7_1F 156105981 156106000 LMNA_PP7_1 156106001 156106170
LMNA_PP7_210R 156106171 156106190
LMNA_PP7_81F 156106052 156106081 LMNA_PP7_81 156106082 156106251
LMNA_PP7_291R 156106252 156106271
LMNA_PP8_1F 156106608 156106626 LMNA_PP8_1 156106627 156106797
LMNA_PP8_208R 156106798 156106815
LMNA_PP8_82F 156106688 156106709 LMNA_PP8_82 156106710 156106871
LMNA_PP8_286R 156106872 156106893
LMNA_PP9_1F 156106868 156106887 LMNA_PP9_1 156106888 156107040
LMNA_PP9_192R 156107041 156107059
LMNA_PP10_1F 156107323 156107342 LMNA_PP10_1 156107343 156107531
LMNA_PP10_228R 156107532 156107550
LMNA_PP10_147F 156107463 156107483 LMNA_PP10_147 156107484 156107652
LMNA_PP10_350R 156107653 156107672
LMNA_PP10_230F 156107552 156107570 LMNA_PP10_230 156107571 156107756
LMNA_PP10_459R 156107757 156107788
LMNA_PP11_1F 156108192 156108209 LMNA_PP11_1 156108210 156108396
LMNA_PP11_223R 156108397 156108415
LMNA_PP11_176F 156108367 156108384 LMNA_PP11_176 156108385 156108547
LMNA_PP11_381R 156108548 156108575
LMNA_PP11_241F 156108432 156108451 LMNA_PP11_241 156108452 156108637
LMNA_PP11_465R 156108638 156108657
LMNA_PP12_1F 156108478 156108495 LMNA_PP12_1 156108496 156108677
LMNA_PP12_225R 156108678 156108763
LMNA_PP12_161F 156108638 156108657 LMNA_PP12_161 156108658 156108828
LMNA_PP12_371R 156108829 156108848
LMNA_PP12_301F 156108788 156108801 LMNA_PP12_301 156108802 156108977
LMNA_PP12_519R 156108978 156108997
LMNA_PP12_469F 156108946 156108964 LMNA_PP12_469 156108965 156109136
LMNA_PP12_682R 156109137 156109159
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rs4641 were found once in S9 (Table 3). All these SNPs were absent
in 12 healthy controls except rs4641 which was identiﬁed in one
control individual. The loci of the SNPs have been depicted in the
schematic diagram of the protein demarcating their respective posi-
tions (Fig. 3).
Results obtained from next generation sequencing were further
validated by Sanger sequencing. The desired exons of LMNA were
ampliﬁed by PCR as reported in Perrot et al. [9] and were sent for
Sanger sequencing. The SNPs residing in the exons of LMNA were
all conﬁrmed from the Sanger sequencing, 2 representative chro-
matograms showing the presence of polymorphism at the desired
region are shown in Fig. 4.4. Discussion
Laminopathies are principally caused by sporadic mutations in
LMNA gene in individuals. Nevertheless, numerous SNPs have been re-
ported frompopulation based studieswhich are known to cause speciﬁc
laminopathies like Charcot–Marie–Tooth Disorder, familial partial
Lipodystrophy and Emery–Dreifus Muscular dystrophy (EDMD) [17,
18]. 165 LMNA mutations have been known to be associated with
DCM till date based on studies from Europe, USA and some South East
Asian countries but, there are no reports till date establishing any
association of SNPs in LMNA with IDCM barring one [25]. However,
in a recent report from a Genome Wide Association Study (GWAS)
with DCM patients identiﬁed two different loci 1) rs10927875 and
Fig. 1. A representative ECG of a DCM patient and a control subject. ECG of the patient showed features of LVH with strain pattern.
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This region encompasses several genes among which HSPB7 was
previously suggested to be implicated in DCM whereas rs2234962
was a non-synonymous SNP (c.T757C, p. C151R) which is located
within the sequence of BAG3 on chromosome 10q26 [26]. To date,
there are very few reports regarding the genetic background of
LMNA in Indian population [27,28]. In the present study, we
showed for the ﬁrst time the association of variations in LMNA
gene with IDCM in Indian population. We identiﬁed 8 LMNA SNPs
in subjects with IDCM in a small cohort of Indian sub-population.
All these SNPs were shown to be associated with various other dis-
orders in ethnically distinct population but not with DCM.Fig. 2. A representative Echocardiogram of a DCM patient and a control subject. ECHO for the
hypokinesia.We identiﬁed 4 different SNPs which reside in the exon region of
LMNA; the affected exons are 3, 5, 7 and 10 at codon positions 204,
287, 446 and 566 respectively. SNP rs12117552 located in exon 3 of
LMNAwhich was identiﬁed in one patient of our study was ﬁrst report-
ed to be associated with Werner's syndrome in an African-American
female [29]. rs12117552 in exon 3which corresponds to silent substitu-
tion fromG toA at the third base of codon 204 results in same sense var-
iation (rs121117552; L204L). This exon also harbors amutation hotspot
at codon 190, which is critically linked with DCM [9,10]; and thus
justiﬁes the development of DCM in patients harboring this variation.
Previous reports state the involvement of SNP rs538089whichmapped
at exon 5 in LMNAwith bothWerner's syndrome as well as in a subtypepatient sample showed the dilation of LV and presence of mitral regurgitation and global
Table 2
Clinical status.
Serial no. Patient ID Chest X-ray ECG Echocardiography Coronary
angiography
Dilated cardiac
chamber
Global hypokinesia LV ejection
fraction
1 S1 Cardiomegaly Sinus tachycardia √ √ 35% Normal
2 S2 Cardiomegaly, pulmonary
plethora
Sinus tachycardia, left ventricular
hypertrophy
√ √ 22% Normal
3 S3 Cardiomegaly, patchy
pneumonia
LBBB √ √ 30% Normal
4 S4 Cardiomegaly LBBB √ √ 28% Normal
5 S5 Cardiomegaly LBBB √ √ 35% Normal
6 S6 Cardiomegaly LBBB, complete heart block √ √ 30% Normal
7 S7 Cardiomegaly LBBB √ √ 20% Normal
8 S8 Cardiomegaly, patchy
pneumonia
LBBB √ √ 28% Normal
9 S9 Cardiomegaly 2:1 AV block √ √ 32% Normal
10 S10 Cardiomegaly LBBB √ √ 30% Normal
11 Control No cardiomegaly Normal Normal cardiac chamber Good LV systolic function 60%–65% Normal
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population [29,30]. SNP rs538089 results from a change of nucleotide
from T to C at the third base of codon 287; this codon of LMNA is also re-
ported to be associated with a frame shift mutation which causes DCM
[25]. Thus, a simple variation but not mutation at codon 287 of LMNA
justiﬁes its association with DCM. Next, we identiﬁed SNP rs505058 in
our study. In rs505058 an alteration at the third base of codon 446
from T to C results in same sense variation to Aspartic acid at exon 7.
In other reports from GWAS this SNP was found to be associated with
patients afﬂicted with Late Onset of Alzheimer's disease (LOAD) in el-
derlymales [31,32]. It was also found to be involvedwithWerner's syn-
drome and CMT2B1. The codon 446 was shown to be involved with a
mutation D446V in patients suffering from EDMD [33]. EDMD is a con-
dition characterized by weakness of the muscles used for movement
(skeletal muscles) and the heart (cardiac) muscle. Consequently, pa-
tients suffering with DCM also show weak cardiac muscles, thus a vari-
ation at codon position 446might contribute to the diseased phenotype
of DCM.
The most widely studied LMNA SNP in literature is rs4641, which is
also the most frequently encountered SNP in our study. A substitution
of nucleotide C to T at the third base of codon 566 (exon 10) results in
the development of SNP rs4641 [21,29,31,32,34] which still codes for
Histidine. Previous studies in ethnically distinct population have
shown its association with Type 2 Diabetes (T2D), themetabolic abnor-
malities, and obesity-related traits in some [20,21,34–36]; but not all
studies [37,38]. The position associated with rs4641 is very important
as it is located adjacent to a splice site at exon 10; alternative splicing
at this site leads to the production of either lamin A or C transcripts or
protein. A recent report emphasizes the role of T- allele at positionTable 3
Genetic analysis of LMNA.
dbSNP Amplicon ID Position
of SNP in
amplicons
Exon Type Zygosity Genotype Ref Va
rs121117552 LMNA_PP3_1 167 3 SNP Het G/A G A
rs538089 LMNA_PP5_1 144 5 SNP Het T/C T C
rs505058 LMNA_PP7_81 135 7 SNP Het T/C T C
rs4641 LMNA_PP10_147 82 10 SNP Het C/T C T
rs646840 LMNA_PP6_204 221 NA SNP Het G/T G T
rs534807 LMNA_PP6_204 221 NA SNP Het G/A G A
rs80356803 LMNA_PP1_1 56 NA SNP Het T/C T C
rs7339 LMNA_PP12_301 209 NA SNP Het G/C G C
Het SNPs = number of called heterozygous SNPs in target regions or loci, ref = genotype in th
variant allele, ref coverage or var coverage = the total reads covering the position, location =566 in regulating the lamin A to C mRNA ratio in T2D patients [35].
Other reports have shown decreased level of lamin A mRNA in patients
suffering fromDCM [39]. Thus, it can be hypothesized that rs4641might
contribute to the DCM phenotype by regulating the lamin A to C mRNA
ratio although the fact that this is deﬁnitely not to be the sole player
leading to the pathogenesis of the disease. Interestingly, rs4641 is
further associated with Werner's syndrome [29]. This makes rs4641 a
candidate gene locus as a biomarker for various kind of disorder along
with DCM. The other two SNPs rs534807 and rs7339 were reported to
be associated with CMT2B1 a commonly known laminopathy. Most of
these SNPs were previously reported to be involved with various
kinds of disorders except; rs80356803 and rs646840whichwere not re-
ported earlier to be involvedwith anydisorders.We showed for the ﬁrst
time the association of these two SNPs with DCM in Indian population
and reside in the intron of LMNA. rs538089, rs505058 and rs4641 are
the three SNPs identiﬁed in Indian population from our study; were
also previously known to be involved with DCM in a French population
[25]. However we did not observe any other associated symptoms of
laminopathies e.g. muscle degeneration, sensory and motor neuron
mediated voluntary movement of muscles or unusual accumulation of
adipocytes as observed in EDMD, CMT2B1 and FPLD respectively
[40–43]. Although all patients were admitted based on symptoms
which included cough and respiratory distress, these symptoms
are common observations for patients of decompensated Dilated
Cardiomyopathy.
Currently, there are no special criteria to distinguish LMNAmutation
associated Cardiomyopathy and other forms of idiopathic Cardiomyop-
athy. Genetic heterogeneity is a hallmark for autosomal dominant
DCM–Conduction Defects (DCM–CD) where nearly 40 genes haveriant Var freq Ref
coverage
Var
coverage
Location Translation
impact
Protein
variant
Patient
ID
44.44444 130 104 Exon L204L WT S8
60.71429 55 85 Exon A287A WT S7
55.69493 883 1110 Exon D446D WT S1
51.00671 292 304 Exon H566H WT S3,S4 & S9
81.12642 315 1354 Intron S1
6.190476 197 13 Intron S1 & S3
7.54717 49 4 Utr_5 S9
50.65327 982 1008 Utr_3 S7
e reference gene, variant= genotype obtained in the patient, var freq = frequency of the
position in the gene.
Fig. 3. Schematic representation of 12 exons of LMNA. The SNPs identiﬁed in our genetic analysis are displayed at their respective position in the gene with arrows.
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majority of these genes encode cytoskeletal and sarcomeric proteins.
However, mutations in LMNA coding for lamin A/C, DES coding for Des-
min and SCN5A encoding cardiac sodium channel protein are still
regarded as primary causes for DCM–CD. Therefore, the genes involved
in mechanical force transduction and propagation are mutated thereby
precipitating the disease. DCM associated with all levels of conduction
system defects like sick sinus syndrome, atrioventricular block or
bundle branch blocks could be traced back to mutations in LMNA. The
conduction disease defects call for pacemaker implantation in patients
with LMNAmutations. In young healthy LMNA carriers, arrhythmias in-
cluding atrial ectopy, atrial ﬁbrillation, non-sustained ventricular
tachycardia and ventricular arrhythmias can be the earliest manifesta-
tion of the LMNA mutation prior to chamber dilatation [10,23]. Once
DCM is clinically conﬁrmed the management follows standard care for
heart failure including ACE inhibitors, beta blockers, diuretics andFig. 4.A representative chromatogramof 2 SNPs identiﬁed inDCMpatients validated by Sanger
reverse primer for exon 7.aldosterone antagonists as per the recommendation of New York
Heart Association functional class. However, it is not clear whether
early administration of these therapeutic agents prior to conﬁrmation
of the disease can modify the aggressive nature of LMNA Cardiomyopa-
thy. As LMNA Cardiomyopathy is diagnosed genetically, the sequencing
of exons and intron–exon junctions has been reported in various case
studies. Due to the advent of deep sequencing technology these se-
quencing data present a reliable database for cataloging mutations or
SNPs in the LMNA gene which might lead to the disease.
The ultimate goal of medical research is to uncover novel diagnostic
and therapeutic modalities which will be of clinical utility. Therefore,
detailed genetic analysis of the LMNA gene in the affected patients at
the early stagemight help in bettermanagement and hence therapeutic
intervention. Such genetic screening based on LMNA gene could be also
extended to the nearest kins of the patient to verify any hereditary pen-
etrance which could be then treated as cases of familial DCM. Wesequencing; rs538089 validatedusing forward primer for exon5; rs505058 validatedusing
105A. Banerjee et al. / IJC Heart & Vasculature 7 (2015) 99–105conclude that polymorphism in LMNA is one of the major genetic risk
factor for the pathogenesis of DCM other than mutation in LMNA.
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